Please find attached Press Release
SUPRIYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Supriya Lifescience reported its audited financial results for Q4 FY25 and full year FY25, approved by the Board on May 27, 2025. Full-year revenue grew 22% year-on-year to Rs 696.48 crore, while EBITDA surged 51% to Rs 260.80 crore with margin expanding sharply to 37.4% from 30.3%. Net profit for the year rose 57.8% to Rs 187.96 crore, with EPS at Rs 23.35 versus Rs 14.80 last year. In Q4 alone, revenue rose 16.4% to Rs 184.11 crore and PAT jumped 38.4% to Rs 50.38 crore, with EBITDA margin improving to 36.7%. The API manufacturer, which exports to over 86 countries and holds USFDA, EUGMP, and other key certifications, called it a landmark year driven by diversified product portfolio and operational excellence.
Strong double-digit growth across revenue, EBITDA, and PAT, coupled with significant margin expansion, signals robust business momentum and is likely to be viewed positively by investors. Shareholders benefit from a sharp jump in full-year EPS, indicating improved profitability per share.